Výsledky vyhledávání

Abstract PS12-20: A dose escalation study of the novel oral SERD-ZN-c5 in women with ER-positive, HER2-negative advanced/metastatic breast cancer

Autor: Kevin Kalinsky, Joanne E. Mortimer, José Agustín Quincoces Suárez, Julie R. Nangia, Matt Suster, Mieke Ptaszynski, Pavani Chalasani, Vandana G. Abramson

Publikováno v: Cancer Research. 81:PS12-20

Background: ZN-c5 is an orally bioavailable selective estrogen receptor degrader (SERD) that binds potently to the estrogen receptors alpha and beta. It shows improved activity over fulvestrant in human tumor xenograft models and activity in tumor mo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ad34b91fd6b132f938e46b6c40860692
https://doi.org/10.1158/1538-7445.sabcs20-ps12-20

Zobrazit plný text záznamu

Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia

Autor: Roy Fleischmann, Bradley Kerr, Matt Suster, Li-Tain Yeh, Zancong Shen, Jeffrey N. Miner, Kimberly Manhard, Elizabeth Polvent, Barry D. Quart, Scott Baumgartner, Vijay Hingorani

Publikováno v: Rheumatology. 53:2167-2174

Objective. The aim of this study was to evaluate the pharmacodynamics (PDs), pharmacokinetics (PKs) and safety of lesinurad (selective uric acid reabsorption inhibitor) in combination with febuxostat (xanthine oxidase inhibitor) in patients with gout

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de1c255ca16bb15e121b3ae4a165ac2d
https://doi.org/10.1093/rheumatology/ket487

Zobrazit plný text záznamu

Voreloxin (formerly known as SNS-595) in Combination with Cytarabine Demonstrates Preliminary Clinical Responses in a Phase 1 Study in Relapsed/Refractory Acute Myeloid Leukemia

Autor: Judith Fox, Matt Suster, Jeffrey E. Lancet, Craig Jerome Berman, Larry D. Cripe, Glenn Michelson, Gail J. Roboz, Nguyen Tan, Judith E. Karp, Rachael Hawtin

Publikováno v: Blood. 112:1955-1955

Background: Voreloxin (formerly SNS-595) is a first-in-class replication-dependent DNA damaging agent that causes apoptosis by DNA intercalation and inhibition of topoisomerase II. A previous phase 1 study of single-agent voreloxin demonstrated accep

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c12e11fee1daf9d7d392409100b4fabb
https://doi.org/10.1182/blood.v112.11.1955.1955

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání